3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
2
Status
Completed
14
Terminated
4
Unknown
3
Recruiting
2
Active not recruiting
2
Withdrawn
1
Sponsor Class
OTHER
1
INDUSTRY
1
Study Type
Interventional
2
Sponsor
Cancer Type
Genitourinary
2
Conditions
Non-Muscle Invasive Bladder Neoplasms
4
Urinary Bladder Neoplasms
2
Side Effect of Drug
1
Parkinson Disease 4, Autosomal Dominant Lewy Body
1
Interventions
Gemcitabine
18
pembrolizumab
16
Cisplatin
16
Nivolumab
15
atezolizumab
11
durvalumab
9
Specimen Handling
9
Magnetic Resonance Spectroscopy
9
Cystectomy
8
Carboplatin
7
Ipilimumab
6
Fluorouracil
6
avelumab
5
Mitomycin
5
sacituzumab govitecan
4
erdafitinib
4
enfortumab vedotin
4
Surgical Procedures, Operative
4
Immunoglobulin G
4
Disulfides
4
Biopsy
4
tremelimumab
3
cabozantinib
3
Transurethral Resection of Bladder
3
Surveys and Questionnaires
3
Radiation
3
Platinum
3
Paclitaxel
3
Leucovorin
3
Docetaxel
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Active not recruiting
×
Urinary Bladder Neoplasms
×
BCG Vaccine
×
Clear all
NCT04165317
2026-01-22
CREST
Pfizer
Phase 3
Active not recruiting
1,068 enrolled
20 charts
NCT03799835
2024-12-11
ALBAN
UNICANCER
Phase 3
Active not recruiting
517 enrolled